To produce Kymriah? or Yescarta?, a patient?s T cells are engineered to express Chimeric Antigen Receptors (CARs) specific for the CD19 B lymphocyte molecule (1).

Treatment options for CRC are highly dependent on the stage of disease, but many patients receive cocktails of chemotherapies and in some cases radiation treatment along with chemotherapy. A number of preclinical xenograft models exist that allow pharmaceutical and biotech companies to investigate new treatment approaches for CRC.

Ovarian cancer is an unmet medical need and particularly lethal because it is often detected only when disease is quite advanced. In 2017, approximately 22,440 women will be diagnosed with ovarian cancer in the United States, and approximately 14,080 deaths will occur.

Preclinically there are few options to test effects of clinically relevant radiation therapy approaches. Labcorp has a Small Animal Radiation Research Platform (SARRP; Xstrahl) in house and can provide a solution to this currently unmet preclinical need.

Immunotherapy drugs provide an alternate approach to treatment, aiming to bolster the immune system to eradicate disease. In the past, use of antibody therapies has been limited in GBM due to the obstruction caused by the blood brain barrier to therapy delivery.

One of the most commonly utilized syngeneic mouse models of mammary cancer is 4T1. We have characterized our 4T1-luc2 model to support studies with novel immuno-oncology agents.

Adoptive cell therapy (ACT) with T-cells reprogrammed to express chimeric antigen receptors (CAR T-cells) bind specific antigens on the surface of cancer cells and trigger a cytotoxic response.

Advancements in Using Immuno-oncology Combination Therapies for Breast Cancer

While several treatment options are available to fight hormone- or Her2-driven breast cancers, options are somewhat limited for 

The EMT6 model was derived from a transplanted hyperplastic alveolar metastatic lung nodule in BALB/c mice.⁴   As further data was generated with this model, observations of metastatic foci in the lung visible upon gross necropsy occurred in up to 40% of control mice.  As metastasis is common in breast cancer

Glioblastoma (GBM) patients are known to have a poor prognosis and tumor progression with high mortality and a median survival of only 12-15 months. Currently, anti-GBM therapy includes a multi-modality method involving radiotherapies and surgical removal of the tumor in combination with chemotherapy.¹